treatment
Depression among expectant mothers during and shortly after giving birth is emerging as a pressing global health issue. When it comes to treatment, medical professionals are actively exploring novel treatment approaches to address depressive symptoms in new parents, including the use of psychedelic drugs in one newly-published study. Scientists in China and the United States unveiled a promising intervention: a single low-dose injection of esketamine administered immediately after childbirth appears to significantly reduce major depressive episodes in mothers who had prenatal depression. The n...
Euronews (English)
Kate, the Princess of Wales, disclosed that she has cancer and is undergoing chemotherapy in a video announcement on Friday. However, in the announcement, she did not say what kind of cancer or reveal details of her treatment. What do we know about the princess' health from what was said in her video and what do medical experts believe is happening with her treatment? 'So proud': King Charles hails Kate's courage after cancer newsWhat kind of surgery did Kate have?Kate had what was described as abdominal surgery on January 16. The news wasn't announced until the next day, when Kensington Palac...
Euronews (English)
Emily Hollenbeck lived with a deep, recurring depressionshe likened to a black hole, where gravity felt so strong and her limbs so heavy she could barely move. She knew the illness could kill her. Both of her parents had taken their lives. She was willing to try something extreme: Having electrodes implanted in her brain as part of an experimental therapy. Researchers say the treatment —- called deep brain stimulation, or DBS — could eventually help many of the nearly 3 million Americans like her with depression that resists other treatments. It's approved for conditions such as Parkinson's di...
Euronews (English)
Washington (AFP) - A new treatment shows promise against the deadly neurodegenerative disease ALS, a study based on mice showed Tuesday. Amyotrophic lateral sclerosis, sometimes called Lou Gehrig's disease after the famous baseball player, devastates nerve cells in the brain and spinal cord. It affects about 30,000 Americans at any given time, causing progressive loss of motor and cognitive function. Most patients die within five years of their diagnosis. In the new research, published in the journal PLOS Biology, a team led by Jeffrey Agar of Northeastern University investigated a way to ta...
AFP
Geneva (AFP) - The World Health Organization said Friday it "strongly recommended" Pfizer's Covid-19 antiviral pill Paxlovid for patients with milder forms of the disease who were still at a high risk of hospitalisation. However the UN agency warned it was "extremely concerned" that the inequality in access seen with Covid vaccines would again leave low- and middle-income countries "pushed to the end of the queue". US pharma giant Pfizer's combination of nirmatrelvir and ritonavir was the "superior choice" of treatment for unvaccinated, elderly or immunocompromised people with Covid, the WHO's...
AFP
Washington (AFP) - US biotech firm Regeneron said Tuesday that its synthetic antibody treatment for Covid-19 may be less effective against the new variant, and it plans to conduct tests to determine by how much. "Prior in vitro analyses and structural modeling regarding the individual mutations present in the Omicron variant indicate that there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody-conveyed immunity, including the current REGEN-COV antibodies," the company said in a statement. "Further analyses are ongoing to confirm and quantify this potential ...
AFP
Washington (AFP) - US scientists have developed a new form of drug that promotes the regeneration of cells and reversed paralysis in mice with spinal injuries, allowing them to walk again within four weeks of treatment. The research was published in the journal Science on Thursday, and the team of Northwestern University scientists behind it hope to approach the Food and Drug Administration as early as next year to propose human trials. "The aim of our research was to develop a translatable therapy that could be brought to the clinic to prevent individuals from becoming paralyzed after major t...
AFP
Washington (AFP) - A synthetic antibody treatment developed by Regeneron reduced the risk of developing symptomatic Covid by more than 80 percent up to eight months after receiving the treatment, the US biotech firm said Monday. The results are "particularly important to those who do not respond to COVID-19 vaccines including people who are immunocompromised," said Myron Cohen, a University of North Carolina at Chapel Hill scientist who is leading a government-sponsored study into the treatment. The study included 842 people who received a placebo and 841 who received the treatment, known as R...
AFP
Washington (AFP) - The United States on Wednesday announced an agreement with Merck to buy 1.7 million courses of an experimental antiviral pill against Covid-19. The $1.2 billion dollar deal is for a drug called molnupiravir, which is currently being tested in a global Phase 3 clinical trial of 1,850 people, with results expected by fall. "This agreement is part of the Biden Administration's whole-of-government approach to develop new COVID-19 treatments and to respond to the health needs of the public," the Department of Health and Human Services said. The US will only complete the deal if m...
AFP
Convalescent plasma therapy: fighting COVID-19 with the help of antibodies is it really that simple? By Pradeep Krishnatray It’s logic is so simple and so intuitively appealing that it seems almost lifesaving. When a body is attacked by a virus, it produces antibodies to ward off the infection. That is Immunology 101. If the human body produces antibodies, why not draw them out from a recovered person and transfuse it into an infected person to treat the infection? Simple, right? Well, not really. The idea is neither novel nor absurd. We have done it several times before. We pluck an egg from ...
Health Analytics
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら